Rituximab in relapsed lymphocyte-predominant Hodgkin lymphoma: long-term results of a phase 2 trial by the German Hodgkin Lymphoma Study Group (GHSG)

Publication

Rituximab in relapsed lymphocyte-predominant Hodgkin lymphoma: long-term results of a phase 2 trial by the German Hodgkin Lymphoma Study Group (GHSG)

Journal Paper/Review - Jan 1, 2008

Schulz Holger, Engert Andreas, Diehl Volker, Schnell Roland, Borchmann Peter, Rüdiger Thomas, Driessen Christoph, Elter Thomas, Morschhauser Franck, Rehwald Ute, Reiser Marcel

Schulz, Holger

Rehwald, Ute

Morschhauser, Franck

Elter, Thomas

Driessen, Christoph

Medizinische Onkologie und Hämatologie · Dept. I

127

Rituximab in relapsed lymphocyte-predominant Hodgkin lymphoma: long-term results of a phase 2 trial by the German Hodgkin Lymphoma Study Group (GHSG)

Schulz, Holger

Rehwald, Ute

Morschhauser, Franck

Elter, Thomas

Driessen, Christoph

Rüdiger, Thomas

Borchmann, Peter

Schnell, Roland

Diehl, Volker

Engert, Andreas

Reiser, Marcel